C4 Therapeutics (CCCC) Net Cash Flow Growth (1y) (2020 - 2026)
Powered by 
Analysis
C4 Therapeutics (CCCC) Net Cash Flow Growth (1y) (2020 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.77 Bn | 130.92 Bn | 2.84 Bn | 172.72% |
| 2 | Regeneron Pharmaceuticals | 85.51 Bn | 77.52 Bn | 3.93 Bn | 53.21% |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.20 Bn | 53.06 Bn | 52.00 Mn | 47.11% |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - | - |
| 6 | BeOne Medicines | 39.99 Bn | 34.89 Bn | 1.53 Bn | 75.60% |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn | -100.75% |
| 8 | Royalty Pharma | 28.40 Bn | 27.56 Bn | - | 149.49% |
| 9 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn | -104.22% |
| 10 | C4 Therapeutics | 492.07 Mn | 238.41 Mn | - | -35.47% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -35.47% |
| Mar 31, 2026 | -216.90% |
| Dec 31, 2025 | 480.58% |
| Sep 30, 2025 | -43.69% |
| Jun 30, 2025 | 262.37% |
| Mar 31, 2025 | 88.61% |
| Dec 31, 2024 | -106.33% |
| Sep 30, 2024 | -182.79% |
| Jun 30, 2024 | -260.07% |
| Mar 31, 2024 | -287.26% |
| Dec 31, 2023 | 431.40% |
| Sep 30, 2023 | 310.01% |
| Jun 30, 2023 | -140.69% |
| Mar 31, 2023 | 165.48% |
| Dec 31, 2022 | 76.60% |
| Sep 30, 2022 | 93.46% |
| Jun 30, 2022 | -93.89% |
| Mar 31, 2022 | 65.31% |
| Dec 31, 2021 | -171.53% |
| Sep 30, 2021 | -167.77% |